Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models

ChAdOx1 nCoV-19/AZD1222 is an approved adenovirus-based vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently being deployed globally. Previous studies in rhesus macaques revealed that intramuscular vaccination with ChAdOx1 nCoV-19/AZD1222 provided protection against pne...

Descripción completa

Detalles Bibliográficos
Autores principales: van Doremalen, Neeltje, Purushotham, Jyothi N., Schulz, Jonathan E., Holbrook, Myndi G., Bushmaker, Trenton, Carmody, Aaron, Port, Julia R., Yinda, Claude K., Okumura, Atsushi, Saturday, Greg, Amanat, Fatima, Krammer, Florian, Hanley, Patrick W., Smith, Brian J., Lovaglio, Jamie, Anzick, Sarah L., Barbian, Kent, Martens, Craig, Gilbert, Sarah C., Lambe, Teresa, Munster, Vincent J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267380/
https://www.ncbi.nlm.nih.gov/pubmed/34315826
http://dx.doi.org/10.1126/scitranslmed.abh0755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267380/
https://www.ncbi.nlm.nih.gov/pubmed/34315826
http://dx.doi.org/10.1126/scitranslmed.abh0755

Ejemplares similares